Novel investigational therapies for onychomycosis: an update

References

• Zaias N. Onychomycosis. Arch Dermatol. 1972;105(2):263–274.
   PubMedGoogle Scholar
• Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66(3):494–502.
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43(4):641–648.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43(2 Pt 1):244–248.
   PubMed Web of Science ®Google Scholar
• Welsh O. Onychomycosis. Clin Dermatol. 2010;28(2):151–159.
   PubMed Web of Science ®Google Scholar
• Baran R. The nail in the elderly. Clin Dermatol. 2011;29(1):54–60.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol. 1998;139(4):665–671.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Humke S. The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol EJD. 2000;10(5):379–384.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Gupta MA, Summerbell RC, et al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol JEADV. 2000;14(6):466–469.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Taborda P, Taborda V, et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol. 2000;39(10):746–753.
   PubMed Web of Science ®Google Scholar
• Bakr NI, El-Sawy E, Hamdy AF, et al. Skin infections in Egyptian renal transplant recipients. Transpl Infect Dis Off J Transplant Soc. 2011;13(2):131–135.
   PubMed Web of Science ®Google Scholar
• Döner N, Ş Y, Ekmekçi TR. Evaluation of obesity-associated dermatoses in obese and overweight individuals. Turkderm. 2011;45(3):146–151.
   Google Scholar
• Tosti A, Hay R, Arenas-Guzman R. Patients at risk of onychomycosis - risk factor identification and active prevention. J Eur Acad Dermatol Venereol. 2005;19(s1):13–16.
   PubMed Web of Science ®Google Scholar
• Murdan S. 1st meeting on topical drug delivery to the nail. Expert Opin Drug Deliv. 2007;4(4):453–455.
   PubMedGoogle Scholar
• Murdan S. Enhancing the nail permeability of topically applied drugs. Expert Opin Drug Deliv. 2008;5(11):1267–1282.
   PubMed Web of Science ®Google Scholar
• Epstein E. How often does oral treatment of toenail onychomycosis produce a disease-free nail? an analysis of published data. Arch Dermatol. 1998;134(12):1551–1554.
   PubMedGoogle Scholar
• Markham A. Tavaborole: first global approval. Drugs. 2014;74(13):1555–1558.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Paquet M, Simpson FC. Therapies for the treatment of onychomycosis. Clin Dermatol. 2013;31(5):544–554.
   PubMed Web of Science ®Google Scholar
• Novartis. LAMISIL (terbinafine hydrochloride) Tablets, 250 mg [Internet]. Drugs@FDA; [ cited 2013 Mar 15]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020539s021lbl.pdf.
   Google Scholar
• Tosti A, Piraccini BM, Stinchi C, et al. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatol Basel Switz. 1998;197(2):162–166.
   PubMed Web of Science ®Google Scholar
• Arrese JE, Piérard GE. Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology. 2003;207(3):255–260.
   PubMed Web of Science ®Google Scholar
• Somchit N, Norshahida A, Hasiah A, et al. Hepatotoxicity induced by antifungal drugs itraconazole and fluconazole in rats: a comparative in vivo study. Hum Exp Toxicol. 2004;23(11):519–525.
   PubMed Web of Science ®Google Scholar
• Hoekstra WJ, Garvey EP, Moore WR, et al. Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg Med Chem Lett. 2014;24(15):3455–3458.
   PubMed Web of Science ®Google Scholar
• Hulin A, Dailly E, Le Guellec C. Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique. [ Level of evidence for therapeutic drug monitoring of voriconazole]. Thérapie. 2011;66(2):109–114.
   PubMed Web of Science ®Google Scholar
• Warrilow AGS, Hull CM, Parker JE, et al. The clinical candidate VT-1161 is a highly potent inhibitor of candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014;58(12):7121–7127.
   PubMed Web of Science ®Google Scholar
• Garvey EP, Hoekstra WJ, Moore WR, et al. VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. Antimicrob Agents Chemother. 2015;59(4):1992–1997.
   PubMed Web of Science ®Google Scholar
• Vlahovic TC, Joseph WS. Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes. J Drugs Dermatol JDD. 2014;13(10):1186–1190.
   PubMed Web of Science ®Google Scholar
• Lipner SR, Scher RK. Management of onychomycosis and co-existing tinea pedis. J Drugs Dermatol JDD. 2015;14(5):492–494.
   PubMed Web of Science ®Google Scholar
• Rich P. Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early. J Drugs Dermatol JDD. 2015;14(1):58–62.
   PubMed Web of Science ®Google Scholar
• Rodriguez DA. Efinaconazole topical solution, 10%, for the treatment of mild and moderate toenail onychomycosis. J Clin Aesthetic Dermatol. 2015;8(6):24–29.
   PubMedGoogle Scholar
• Jellinek NJ, Korotzer A. Prognostic factors for complete cure following treatment of mild and moderate toenail onychomycosis with efinaconazole topical solution 10. J Drugs Dermatol JDD. 2015;14(8):871–875.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Shear NH. Terbinafine: an update. J Am Acad Dermatol. 1997;37(6):979–988.
   PubMed Web of Science ®Google Scholar
• Balfour JA, Terbinafine FD. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs. 1992;43(2):259–284.
   PubMed Web of Science ®Google Scholar
• Hui X, Lindahl Å, Lamel S, et al. Onychopharmacokinetics of terbinafine hydrochloride penetration from a novel topical formulation into the human nail in vitro. Drug Dev Ind Pharm. 2013;39(9):1401–1407.
   PubMed Web of Science ®Google Scholar
• Iorizzo M, Arraiz G, Frisenda L, et al. An innovative terbinafine transungual solution (P‐3058): dose finding investigation on clinical benefit in patients affected by mild‐to moderate toe onychomycosis [Internet]. American Academy of Dermatology; 2013. Available from: an innovative terbinafine transungual solution (P‐3058): dose finding investigation on clinical benefit in patients affected by mild‐to moderate toe onychomycosis.
   Google Scholar
• Tuncay Tanrıverdi S, Hilmioğlu Polat S, Yeşim Metin D, et al. Terbinafine hydrochloride loaded liposome film formulation for treatment of onychomycosis: in vitro and in vivo evaluation. J Liposome Res. 2015;1–11. [Epub ahead of print].
   PubMedGoogle Scholar
• Anacor Pharmaceuticals Inc. FDA approves Anacor Pharmaceuticals’ KERYDIN^TM (tavaborole) topical solution, 5% for the treatment of onychomycosis of the toenails [Internet]. 2014. [ cited 2014 Nov 24]. Available from: http://investor.anacor.com/releasedetail.cfm?ReleaseID=858211.
   Google Scholar
• Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007;316(5832):1759–1761.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Simpson FC. New pharmacotherapy for the treatment of onychomycosis: an update. Expert Opin Pharmacother. 2015;16(2):227–236.
   PubMed Web of Science ®Google Scholar
• Coronado D, Merchant T, Chanda S, et al. In vitro nail penetration and antifungal activity of tavaborole, a boron-based pharmaceutical. J Drugs Dermatol JDD. 2015;14(6):609–614.
   PubMed Web of Science ®Google Scholar
• Vlahovic T, MPharm TM, Chanda S, et al. In vitro nail penetration of tavaborole topical solution, 5%, through nail polish on ex vivo human fingernails. J Drugs Dermatol JDD. 2015;14(7):675–678.
   PubMed Web of Science ®Google Scholar
• Bianchi L, Orlandi A, Campione E, et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol. 2004;151(1):148–156.
   PubMed Web of Science ®Google Scholar
• Thacher SM, Vasudevan J, Chandraratna RA. Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000;6(1):25–58.
   PubMed Web of Science ®Google Scholar
• Orlandi A, Bianchi L, Costanzo A, et al. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene. J Invest Dermatol. 2004;122(4):1037–1041.
   PubMed Web of Science ®Google Scholar
• Campione E, Paterno EJ, Diluvio L, et al. Tazarotene as alternative topical treatment for onychomycosis. Drug Des Devel Ther. 2015;9:879–886.
   PubMed Web of Science ®Google Scholar
• Kerai LV, Hilton S, Murdan S. UV-curable gel formulations: Potential drug carriers for the topical treatment of nail diseases. Int J Pharm. 2015;492(1–2):177–190.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Isham N, Long L. In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes. Antimicrob Agents Chemother. 2015;59(9):5154–5158.
   PubMed Web of Science ®Google Scholar
• Hui X, Mailback H. In vitro human nail plate penetration of a novel antifungal agent ME1111. bstr 54th Intersci Confer Antimicrob Agents 318 Chemother abstr F-1588; 2014 Sept 5–9; Washington, DC.
   Google Scholar
• Tabata Y, Nomoto M, Chikada T, et al. In Vivo and In Vitro Nail Penetration of ME1111, a Novel 323 Antifungal Agent for Topical Treatment of Onychomycosis. 2014.
   Google Scholar
• Tierney EP, Hanke WC. Fractionated Carbon Dioxide Laser Treatment of Photoaging: Prospective Study in 45 Patients and Review of the Literature. Dermatol Surg. 2011;37(9):1279–1290.
   PubMed Web of Science ®Google Scholar
• Tierney EP, Eisen RF, Hanke CW. Fractionated CO2 laser skin rejuvenation: fractionated CO2 laser skin rejuvenation. Dermatol Ther. 2011;24(1):41–53.
   PubMed Web of Science ®Google Scholar
• Lim E-H, Kim H-R, Park Y-O, et al. Toenail onychomycosis treated with a fractional carbon-dioxide laser and topical antifungal cream. J Am Acad Dermatol. 2014;Mar 18;70:918–923.
   PubMed Web of Science ®Google Scholar
• Takahata S, Tabata Y, Takei-Masuda N, et al., Meiji Seika Pharma Co., Ltd., Tokyo, Japan. Mechanism of action of ME1111, a new antifungal agent for topical treatment of onychomycosis. [Internet]. Abst 54th Intersci Confer Antimicrob Agents Chemother abstr F-1585.; 2014. Available from: http://www.icaaconline.com/php/icaac2014abstracts/data/papers/2014/F-1585.htm.
   Google Scholar
• Sigurgeirsson B, van Rossem K, Malahias S, et al. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. J Am Acad Dermatol. 2013;69(3):416–425.
   PubMed Web of Science ®Google Scholar
• Murdan S. Drug delivery to the nail following topical application. Int J Pharm. 2002;236(1–2):1–26.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Komatsu T, Sumi M, et al. In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur J Pharm Sci. 2004;21(4):471–477.
   PubMed Web of Science ®Google Scholar